# Defibrotide in COVID-19 Pneumonia

> **NCT04335201** · PHASE2 · COMPLETED · sponsor: **IRCCS San Raffaele** · enrollment: 50 (actual)

## Conditions studied

- Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure

## Interventions

- **DRUG:** Defibrotide Injection

## Key facts

- **NCT ID:** NCT04335201
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2021-04-07
- **Final completion:** 2021-05-28
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335201, "Defibrotide in COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04335201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*